Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Analyst Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
$328.41
▲(6.63%Upside)
| Highest Price Target$500.00 | Average Price Target$328.41 | Lowest Price Target$245.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$327
Hold
6.17%
Upside
Reiterated
06/05/25
Alnylam Pharmaceuticals is showing promising revenue growth and strong technical momentum, contributing positively to its stock score. However, high leverage, ongoing profitability challenges, and a negative P/E ratio weigh down the overall evaluation. The company's strategic focus on achieving sustainable profitability and recent successful product launches provide optimism, but caution is advised due to financial and regulatory risks.
RBC Capital
$330
Buy
7.15%
Upside
Reiterated
06/13/25
J.P. Morgan
$330→$338
Buy
9.74%
Upside
Reiterated
06/12/25
Morgan Stanley
$287
Hold
-6.82%
Downside
Reiterated
06/09/25
H.C. Wainwright
$400→$500
Buy
62.34%
Upside
Reiterated
06/03/25
Barclays
$329
Buy
6.82%
Upside
Reiterated
05/27/25
TD Cowen
$371
Buy
20.46%
Upside
Reiterated
05/19/25
Citi
$351→$364
Buy
18.19%
Upside
Reiterated
05/19/25
Stifel Nicolaus
$345
Buy
12.02%
Upside
Reiterated
05/14/25
Evercore ISI
$280
Buy
-9.09%
Downside
Reiterated
05/06/25
BMO Capital
$300
Buy
-2.59%
Downside
Reiterated
05/06/25
Chardan Capital
$300→$325
Buy
5.52%
Upside
Reiterated
05/02/25
Scotiabank
$342
Buy
11.04%
Upside
Reiterated
05/02/25
UBS
$331→$349
Buy
13.32%
Upside
Reiterated
05/02/25
Piper Sandler
$304
Buy
-1.30%
Downside
Reiterated
05/02/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$327
Hold
6.17%
Upside
Reiterated
06/05/25
Alnylam Pharmaceuticals is showing promising revenue growth and strong technical momentum, contributing positively to its stock score. However, high leverage, ongoing profitability challenges, and a negative P/E ratio weigh down the overall evaluation. The company's strategic focus on achieving sustainable profitability and recent successful product launches provide optimism, but caution is advised due to financial and regulatory risks.
RBC Capital
$330
Buy
7.15%
Upside
Reiterated
06/13/25
J.P. Morgan
$330→$338
Buy
9.74%
Upside
Reiterated
06/12/25
Morgan Stanley
$287
Hold
-6.82%
Downside
Reiterated
06/09/25
H.C. Wainwright
$400→$500
Buy
62.34%
Upside
Reiterated
06/03/25
Barclays
$329
Buy
6.82%
Upside
Reiterated
05/27/25
TD Cowen
$371
Buy
20.46%
Upside
Reiterated
05/19/25
Citi
$351→$364
Buy
18.19%
Upside
Reiterated
05/19/25
Stifel Nicolaus
$345
Buy
12.02%
Upside
Reiterated
05/14/25
Evercore ISI
$280
Buy
-9.09%
Downside
Reiterated
05/06/25
BMO Capital
$300
Buy
-2.59%
Downside
Reiterated
05/06/25
Chardan Capital
$300→$325
Buy
5.52%
Upside
Reiterated
05/02/25
Scotiabank
$342
Buy
11.04%
Upside
Reiterated
05/02/25
UBS
$331→$349
Buy
13.32%
Upside
Reiterated
05/02/25
Piper Sandler
$304
Buy
-1.30%
Downside
Reiterated
05/02/25
Best Analysts Covering Alnylam Pharma
1 Month
xxx
Success Rate
15/26 ratings generated profit
Average Return
+0.78%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +0.78% per trade.
3 Months
xxx
Success Rate
20/29 ratings generated profit
Average Return
+9.81%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.97% of your transactions generating a profit, with an average return of +9.81% per trade.
1 Year
Success Rate
18/20 ratings generated profit
Average Return
+25.36%
reiterated a buy rating last month
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +25.36% per trade.
2 Years
xxx
Success Rate
20/20 ratings generated profit
Average Return
+47.47%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALNY Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
6
8
9
6
5
Buy
28
48
48
51
31
Hold
6
10
14
12
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
66
71
69
44
Each month's total comprises the sum of three months' worth of ratings.
ALNY Financial Forecast
ALNY Stock Forecast FAQ
What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 328.41.
What is ALNY’s upside potential, based on the analysts’ average price target?
Alnylam Pharmaceuticals has 6.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALNY a Buy, Sell or Hold?
Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
What is Alnylam Pharmaceuticals’s price target?
The average price target for Alnylam Pharmaceuticals is 328.41. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $500.00 ,the lowest forecast is $245.00. The average price target represents 6.63% Increase from the current price of $307.99.
The highest analyst price target is $500.00 ,the lowest forecast is $245.00. The average price target represents 6.63% Increase from the current price of $307.99.
What do analysts say about Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
How can I buy shares of ALNY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.